| CRISPR Medicine | This is an overview of articles related to blood disorders
Located in the ETH Innovation & Entrepreneurship Lab in Zürich (Switzerland), Ariya Bio's goal is to develop safe and effective gene-editing therapies...
There are currently four clinical-stage gene-editing candidates in clinical trials for sickle cell disease, which affects millions of people worldwide...
Editas Medicine recently announced positive initial safety and efficacy data for its CRISPR-edited cell therapy EDIT-301. The data was obtained from...
In this clinical update, we look at recent advances in two clinical-stage gene-editing programmes. Editas Medicine's sickle cell disease candidate...
In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...
In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...
Some of the best links we picked up around the internet
On Monday, Beam Therapeutics announced that the U.S. FDA had cleared BEAM-101 for clinical evaluation as a treatment for sickle cell disease. BEAM-101...
